Patent ID: 11919931
Assignee: PIERIS PHARMACEUTICALS GMBH
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A fusion polypeptide that is capable of binding both CD137 and glypican-3 (GPC3), wherein the fusion polypeptide comprises at least two subunits in any order, wherein the first subunit is specific for CD137 and the second subunit is specific for GPC3 and wherein the second subunit comprises an amino acid sequence of a GPC3-specific lipocalin mutein comprising at least one of the following mutated amino acid residues in comparison with the linear polypeptide sequence of mature human lipocalin 2 (hNGAL) (SEQ ID NO: 2):
Leu 36→Val or Arg; Ala 40→Leu, Val or Gly; Ile 41→Leu, Arg, Met, Gly or Ala; Gln 49→Pro or Leu; Tyr 52→Arg or Trp; Asn 65→Asp; Ser 68→Val, Gly, Asn or Ala; Leu 70→Arg, Ser, Ala or Val; Arg 72→Asp, Trp, Ala, or Gly; Lys 73→Gly, Arg, Asn, Glu or Ser; Cys 76→Val or Ile; Asp 77→His, Met, Val, Leu, Thr or Lys; Trp 79→Lys, Ser or Thr; Arg 81→Gly; Cys 87→Ser; Asn 96→Arg, Asp, Gln or Pro; Tyr 100→Gly, Glu, Pro or Gln; Leu 103→Glu, Gln, Asn, Gly, Ser or Tyr; Ser 105→Ala; Tyr 106→Asn, Ser or Thr; Lys 125→Glu; Ser 127→Arg or Tyr; Tyr 132→Trp or Ile; Lys 134→Ala or Phe; Thr 136→Ile; and Cys 175→Ala.